Preclinical studies of166Ho-chitosan for treatment of hepatocellular carcinoma by Yousefnia, H. et al.
See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/303699238
Preclinical studies of 166Ho-chitosan for treatment of hepatocellular
carcinoma
Article · January 2016
CITATION
1
READS
31
9 authors, including:
Some of the authors of this publication are also working on these related projects:
Radiopharmacy View project
Production and Quality control of copper radiopharmaceuticals View project
Hassan Yousefnia
Amirkabir University of Technology
105 PUBLICATIONS   483 CITATIONS   
SEE PROFILE
Samaneh Zolghadri
Amirkabir University of Technology
70 PUBLICATIONS   246 CITATIONS   
SEE PROFILE
Ali Bahrami Samani
Amirkabir University of Technology
97 PUBLICATIONS   500 CITATIONS   
SEE PROFILE
Amirreza Jalilian
International Atomic Energy Agency (IAEA)
359 PUBLICATIONS   2,075 CITATIONS   
SEE PROFILE
All content following this page was uploaded by Amirreza Jalilian on 28 March 2019.
The user has requested enhancement of the downloaded file.
  
 
 
 
Preclinical studies of 166Ho-chitosan for treatment of  
hepatocellular carcinoma 
 
Hassan Yousefnia1, Ahmad Bitarafan-Rajabi2, Mir Sepehr Pedram3,  
Samaneh Zolghadri1, Ali Bahrami-Samani1, Amir Reza Jalilian1,  
Mohammad Mazidi1, Amir Darbandi Azad4, Mohammad Ghannadi-Maragheh1 
 
 
 
1Radiation Application Research School, Nuclear Science and Technology Research Institute, Tehran, Iran 
2Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center,  
Iran University of Medical Sciences, Tehran, Iran 
3Department of Surgery and Radiology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran 
4Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran 
 
 
 
(Received 30 November 2014, Revised 12 October 2015, Accepted 18 October 2015) 
 
 
 
ABSTRACT 
 
Introduction: Recently, due to the special characteristics of 166Ho and chitosan, 166Ho-chitosan complex was developed for 
treatment of tumors such as hepatocellular carcinoma. This complex has been lately prepared with high radiochemical purity 
in our lab. The preclinical studies of the complex however should be performed to evaluate the tracer concentration in target 
and normal tissues before human use. 
Methods: In this study, 166Ho-chitosan was prepared and its preclinical studies for treatment of hepatocellular carcinoma 
was carried out by injection of the radiopharmaceutical into the rabbit`s liver via two different methods, surgery and 
venography. Leakage of the injected activity from the injection site in the rabbit organs was investigated using SPECT and 
SPECT-CT imaging up to 24 hours. 
Results: Both SPECT and SPECT-CT imaging of the rabbits showed that there was no significant leakage of the injected 
activity. Almost all the activity would remain in the injection site at least 24 h post injection.  
Conclusion: Considering all of the excellent features of the complex, this radiopharmaceutical is suggestive for treatment of 
hepatocellular carcinoma by radioembolization method. 
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INTRODUCTION 
Hepatocellular carcinoma (HCC) is a malignant 
tumor of the hepatocyte. It is a common malignancy 
worldwide causing almost half a million deaths 
annually. Although surgery (hepatectomy or liver 
transplantation) is the principle form of treatment, the 
majority of patients may not eligible for surgery due 
to extent of tumor and dysfunction of liver [1]. 
Transarterial chemoembolization (TACE) is the most 
widely used modality in the treatment of unresectable 
HCC, and has been shown to improve survival in a 
meta-analysis [2] and a randomized controlled trial 
[3]. Internal radiation therapy with radioactive agents 
such as 90Y and 131I, as an alternative to 
chemotherapeutic drugs, has the advantage of 
targeting the liver tumor by the selective dose 
delivery to the tumor site [4, 5]. This type of therapy 
has been utilized for palliative treatment of 
inoperable HCC and for adjuvant therapy following 
curative resection of HCC. A randomized study has 
shown a markedly better tolerance for I-131 lipiodol 
than for TACE with equal long term outcome [5].  
Recently, due to the suitable decay characteristics of 
166Ho (Eβ
-
max = 1.84 MeV, T1/2 = 26.8 h) and special 
specifications of chitosan, which make it an excellent 
vehicle for retaining the radioactive material within 
the tumor, 166Ho-chitosan complex has been 
developed for treatment of diseases such as HCC and 
rheumatoid arthritis [6, 7]. Furthermore, this complex 
has demonstrated effectiveness for malignancies such 
as gliomas [8] and prostate cancer [9].  
Biodistribution and kinetics of 166Ho-chitosan 
complex after intrahepatic administration into rats 
and mice was studied before in the Korea atomic 
energy institute. In that research, both 166Ho-chitosan 
and 166Ho were injected directly into the liver by a 
surgical technique using 27-gauge needle. The results 
indicated the retention of the most of 166Ho-chitosan 
activity at the administration site for over 72 h. 
Intrahepatic administration of free unbound 166Ho 
however, showed high radioactive concentrations in 
the blood as well as many other tissues [6]. 
In the other research, the effectiveness of 166Ho-
chitosan complex, for the possibility of its use in 
radiosynovectomy, was investigated after intra-
articular injection into the rat knee joints. 
Biodistribution studies showed that the most of the 
injected activity would remain in the injection site 
even after 144 h. No detectable amounts of activity 
were observed in spleen and lung showing no leakage 
of the complex from the joints [10]. 
Nowadays, 166Ho-chitosan is used for treatment of 
HCC in South Korea. In a phase I/II clinical trial, the 
complex was injected percutaneously into small 
HCC, resulting in complete necrosis in 77.5% of 
cases (31/40) with minimal toxicity [11]. In the other 
work, the response rate of 78% (42/54) was observed 
after transarterial administration of the complex in 
patients with single, large HCC [12]. Despite the 
promising result of the complex in patients with 
HCC, due to the short half-life of 166Ho, the 
possibility of transmission to other countries is 
unlikely. 
However, this radiopharmaceutical was lately 
prepared with high radiochemical purity in our lab 
for treatment of joints by radiosynovectomy [10], but 
the application of the complex for treatment of HCC 
has not been reported. Preclinical study for 
evaluation of the radioactivity distribution in target 
and normal tissues is carried out and previously 
reported [13]. Accordingly, 166Ho-chitosan was 
prepared and its preclinical studies for treatment of 
HCC was carried out by injection of the 
radiopharmaceutical to male New Zealand rabbit’s 
liver via two different method (surgery and 
venography). 
METHODS 
Production of 166Ho was carried out at the Tehran 
Research Reactor (TRR) using natHo(n, gamma)166Ho 
nuclear reaction. Natural holmium nitrate with purity 
of >99.99% was obtained from Aldrich Co. Chitosan 
(medium molecular weight, MW=400 kDa, DDA= 
%85) was obtained from Fluka (Bucks, Switzerland). 
Chromatography paper, Whatman No. 1 was 
obtained from Whatman (Maidstone, UK). Radio-
chromatography was performed by using a bioscan 
AR-2000 radio TLC scanner instrument (Bioscan, 
Washington, DC, USA). A high purity germanium 
(HPGe) detector coupled with a Canberra™ (model 
GC1020-7500SL) multichannel analyzer and a dose 
calibrator ISOMED 1010 (Dresden, Germany) were 
used for counting the activity. All other chemical 
reagents were purchased from Merck (Darmstadt, 
Germany). Calculations were based on the 81 keV 
peak for 166Ho. All values were expressed as mean ± 
standard deviation (Mean ± SD) and the data were 
compared using student T-test. Statistical 
significance was defined as P<0.05. Animal studies 
were performed in accordance with the United 
Kingdom Biological Council's Guidelines on the Use 
of Living Animals in Scientific Investigations, 2nd 
edn.  
 
Production and quality control of 166HoCl3 
solution 
 Holmium-166 was produced by neutron irradiation 
of 100 µg of natural natHo(NO3)3 (
165Ho, 99.99%) 
according to reported procedures [14] in the Tehran 
Research Reactor at a thermal neutron flux of 4-
5×1013 n.cm-2.s-1. The irradiated target was dissolved 
in 200 µL of 1.0 M HCl, to prepare 166HoCl3 and 
diluted to the appropriate volume with ultra pure 
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water, to produce a stock solution. The mixture was 
filtered through a 0.22 µm biological filter and sent 
for use in the radiolabeling step. The radionuclidic 
purity of the solution was tested for the presence of 
other radionuclides using beta spectroscopy as well 
as HPGe spectroscopy for the detection of various 
interfering beta and gamma emitting radionuclides. 
The radiochemical purity of the 166HoCl3 was 
checked using 2 solvent systems for ITLC (A: 10 
mM DTPA pH.4 and B: ammonium acetate 
10%:methanol (1:1)). 
 
Preparation and quality control of 166Ho-chitosan 
complex 
166Ho-chitosan complex was prepared according to 
the previously reported literature [10]. Briefly, 35 mg 
of a stock solution of chitosan (10 mg/mL in 1% 
acetic acid) was added to 2-5 mCi of 166HoCl3 and 
maintained at room temperature for 30 minutes. 
Radiochemical purity of the complex was checked by 
ITLC method and using a mixture of methanol: 
water: acetic acid (4:4:2) as the mobile phase. The 
final complex was kept at room temperature for 24 h, 
while the radiochemical purity was checked using 
frequent ITLC analysis. 
 
Injection of 166Ho-chitosan to rabbit`s liver via 
surgery 
Two male New Zealand white rabbits with 14 weeks 
of age and weighing about 2000 g were used in this 
study. The anesthesia was induced with intra-
muscular (IM) injection of ketamine (50 mg/kg) and 
xylazine (5 mg/kg) and was maintained with 
isofluran (1-5%) after placement of an endotracheal 
tube. The ventral region was prepared for aseptic 
surgery. 200 µCi of 166Ho-chitosan was injected in 
the portal vein after a 3 cm laparotomy incision. The 
incision site was closed by means of standard method 
(the linea alba, subcutaneous and skin were sutured 
separately). 25 mg/kg of cefazoline was injected (IV) 
as prophylactic antibiotic. Leakage of the injected 
activity from the injection site into the rabbit organs 
was investigated using SPECT imaging up to 24 
hours post-injection. Vital signs of the animals were 
checked during the surgery and 72 h post-injection. 
The blood activities were measured by counting 2 
mL blood samples with an HPGe detector at 1 and 24 
h post-injection. 
 
Injection of 166Ho-chitosan to rabbit’s liver via 
venography 
Radioambolisation was performed in a male New 
Zealand rabbit with 14 weeks of age and weighing 
about 2000 g. The animal was anesthetized with IM 
injection of ketamine (50 mg/kg), xylazine (5 mg/kg) 
and atropine (0.4 mg/kg). A 4F catheter was 
introduced through the right femoral vein by cut 
down technique. Then a 0.014 guide wire (BMW 
abbott vascular, ca, USA) was placed into the right 
judkins catheter (cordis corporation, USA) and the 
both were entered into the sheet, followed by the 
guide wire in the vein under the fluoroscopy. To find 
the true path of the injection, contrast material 
(visipaque GE Health care, cork, Ireland) was used. 
After getting into the hepatic portal vein, catheter was 
removed and Micro catheter (2/3F) was placed into 
the venues and 166Ho-chitosan (200 µCi) was injected 
to the left lobe of the liver. Leakage of the injected 
activity from the injection site into the rabbit organs 
was investigated using SPECT-CT imaging 20 min 
and 24 h post-injection. Vital signs of the animal 
were monitored during the venography and 72 h post-
injection. 
 
SPECT-CT imaging Procedure 
The biodistribution of the complex was studied by 
planar and SPECT images after injection of 166Ho-
chitosan via venography. The imaging was performed 
by SPECT-CT system (Simbia T2, Siemens 
Healthcare, Germany) equipped with low energy-
high resolution (LEHR) collimators. Planar imaging 
was performed in both anterior and posterior 
positions after injection of 166Ho-chitosan. Matrix 
size was 256*256 (pixel size = 1.2 mm at zoom 
factor = 1.33). The total time for planar imaging was 
five minutes per acquisition. Symmetric energy 
window with photo-peak at 81± %15 keV of 166Ho 
was selected.  
SPECT imaging was acquired with 64 projections (30 
seconds per view) and 360-degree detector rotation 
was orbited at step and shoot modes. Imaging matrix 
size was determined at 64 × 64 (pixel size = 4.8 mm) 
and the zoom factor was 1.33. All the data were 
reconstructed with filtered back-projection (FBP), 
using Butterwoth filter (cut off = 0.5, order = 5) at 
trans-axial, sagittal and coronal slices. Following 
SPECT examination, CT acquisition was performed 
for image fusion, using current intensity at 16 mAs, 
peak voltage of 130 kVp, and slice thickness of 5 
mm. SPECT-CT images were fused automatically 
using the registered Siemens software (Syngo MI 
workplace) at trans-axial, sagittal and coronal slices. 
 
RESULTS AND DISCUSSION 
Production and quality control of 166Ho 
166Ho was prepared in a research reactor with the 
specific activity of 3-5 GBq/mg. The radionuclidic 
purity was checked by counting the samples on the 
HPGe detector for 5 h, demonstrated the purity of 
more than 99.98%. Besides, the results of thin layer 
chromatograghy indicated the radiochemical purity of 
more than 98% (Figure 1). 
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Fig 1. ITLC chromatograms of 166HoCl3 solution in DTPA solution 
(pH.4) (above) and 10% ammonium acetate : methanol (1:1) 
solution (below) using Whatman No. 2. 
 
Preparation and quality control of 166Ho- chitosan 
complex 
166Ho-chitosan complex was prepared with the 
specific activity of approximately 35 GBq/mol. The 
results of thin layer chromatography showed that the 
complex is majorly prepared in 30 min with 
radiochemical purity of higher than 99% (Figure 2). 
The stability of the prepared complex under 
optimized reaction conditions was studied and 
excellent stability was observed at room temperature 
even after 24 h. 
 
Imaging of 166Ho-chitosan in male New Zealand 
rabbits 
SPECT imaging of 166Ho-chitosan after injection to 
the rabbit’s liver via surgery showed the retention of 
radioactivity in the injection site after 24 h post 
injection (Figure 3). Region of interest analysis was 
performed for quantification (SD) of hepatic and 
background uptake after injection. Mean counts ± 
standard deviations were 256.89 ± 112.79 and 162 ± 
60.38 in the anterior and inferior images, 
respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 2. ITLC chromatograms of 166HoCl3 (above) and 
166Ho-
chitosan solution (below) on Whatman No. 2 paper using 
methanol: water: acetic acid (4:4:2) mixture. 
 
Figures 4 and 5 show the SPECT-CT images of 
166Ho-chitosan complex after injection to the rabbit’s 
liver via venography. This result also confirmed the 
retention of radioactivity in the injection site 24 h 
post injection. According to the analysis of the 
volume of the interest (VOI) in SPECT-CT imaging, 
the mean counts ± SDs of the liver were 
2427±446.95 and 1404±292.05 at 20 min and 24 h 
post injection, respectively. Accordingly, SPECT-CT 
images were shown the stability of the radiolabeled 
complex in the rabbit’s liver even 24 h post-injection. 
Also, the blood activity measurements were 
calculated as % ID/mL showed the values of 63 × 10-
4 and 11 × 10-4 at 1 and 24 h post-injection, 
respectively. 
Intra-arterial radionuclide therapy by means of beta-
emitter radionuclides has been applied as a promising 
alternative for the treatment of liver cancer or liver 
metastases [15]. Various radionuclides such as 90Y, 
153Sm, 165Dy, 166Ho and 177Lu have been used for this 
purpose. Among these radionuclides, 166Ho besides 
considerable decay characteristics can be easily 
produced by neutron bombardment of 165Ho with 
natural abundance of 100% at a research reactor.  
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Fig 3. The anterior (A) and inferior (B) views of the radionuclide 
distribution in the rabbit’s liver 24 h post-injection of 166Ho-
chitosan. 
 
 
 
Fig. 4. The SPECT-CT images of the radiolabeled complex 
distribution in the rabbit’s liver 20 min (early phase) post-
injection, Trans-axial, sagittal and coronal slices images (left to 
right, respectively). Upper row: SPECT-CT fusion images, middle 
row: CT images and lower row: SPECT images. 
 
Also, gamma rays emitted in the decay process of 
166Ho have suitable energies and low abundance that 
result in possible scintigraphic imaging without 
additional radiation dose to the patient.  
Internal radiotherapy of liver cancer is often followed 
by the administration of radiolabeled complex with 
particulate carriers in specific size. However, 
distribution of the complex with particulate 
characteristics in the injection site is inhomogeneous 
and could lead to partial over-irradiation or under-
irradiation of the tissue [7]. But chitosan is a natural, 
non-allergic biodegradable and biocompatible 
polysaccharide forming complexes with 
radionuclides in solution forms that result in a 
homogenous distribution. Furthermore, converting to 
a gel state at the neutral pH of organ is a unique 
property of chitosan which makes it as a suitable 
tracer for internal therapy. Due to these desirable 
characteristics, 166Ho-chitosan has been widely used 
for treatment of HCC especially in some Far East 
Asian countries. 
 
 
Fig 5. The SPECT-CT images of the radiolabeled complex 
distribution in the rabbit’s liver 24 h (late phase) post-injection, 
Trans-axial, sagittal and coronal slices images (left to right, 
respectively). Upper row: SPECT-CT fusion images, middle row: 
CT images and lower row: SPECT images. 
 
 
166Ho-chitosan complex can be easily prepared with 
high radiochemical purity and high stability. It has 
been snown as an effective radiopharmaceutical for 
the treatment of the patients with HCC, but some 
difficulties have limited the application of this 
complex. For example, injection of this new 
radiopharmaceutical is an interventional procedure 
and needs multidisciplinary specialty cooperation 
namely nuclear physician, surgeon and radiologist. 
In this research, this new complex was prepared and 
preclinical studies for the treatment of HCC were 
evaluated. In order to achieve the best route for the 
administration and to investigate the leakage of 
radionuclide to non-target organs, the complex was 
injected to the rabbit’s liver via two different 
methods (surgery and venography).  
The SPECT images indicated that the complex 
remained at the injection site even 24 h post-injection 
and no detectable amounts of activity were observed 
in the other organs. Also, the blood activity 
measurements showed the values of 63 × 10-4 and 11 
× 10-4 at 1 and 24 h post-injection, respectively, 
which is consistent to the other reported values with 
the maximum rat’s blood samples activity (% ID/mL) 
of about 90 ×10 -4 which decrease to 10 × 10-4 within 
48 h.  
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The prepared 166Ho-chitosan complex showed almost 
the same characteristics as the other reports in the 
literature. The result of previous research on the 
biodistribution studies of the complex in the rats after 
intrahepatic administration has indicated retention of 
the most of the injected dose at the administration site 
with uneven radioactive distribution in the lungs [6]. 
The SPECT imaging showed stability and 
insolubility of the complex at the injection site with 
no activity seen in the lungs or other organs. The 
difference between the observed activities in the 
lung, as mentioned by Suzuki et al., can be related to 
the type of the under studies animals [6].  
Also the results showed that both the surgery and 
venography methods were safe and practical. Since 
the biodistribution data did not depend on the type of 
the administration, due to the ease, the venography 
method can be preferred. According to the results, the 
complex can be used as an effective agent for the 
treatment of liver cancer in the country. 
 
CONCLUSION 
The 166Ho-chitosan complex was prepared with high 
radiochemical yield (>99 %) in the optimized 
condition; 10 mg/mL of chitosan concentration in 
diluted acetic acid solution (pH=3). The prepared 
complex was stable in the final solution at room 
temperature and can be used even 24 hours after 
preparation. Injection of 166Ho-chitosan to rabbit’s 
liver was performed via two different methods and 
the leakage of the injected activity from the injection 
site in the rabbit organs was investigated using 
imaging procedures up to 24 hours demonstrating no 
significant leakage of the injected activity as evident 
by retained activity at the injection site. Considering 
all of the excellent features of the complex, this 
radiopharmaceutical could be an effective alternative 
for treatment of HCC by radioembolization method. 
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